Travere Therapeutics, Inc. (TVTX)
40.77
+1.23
(+3.11%)
USD |
NASDAQ |
Apr 17, 16:00
40.80
+0.03
(+0.07%)
Pre-Market: 20:00
Travere Therapeutics Research and Development Expense (Quarterly) : 57.87M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Revolution Medicines, Inc. | 292.61M |
| ICU Medical, Inc. | 21.09M |
| Tandem Diabetes Care, Inc. | 46.07M |
| iRhythm Holdings, Inc. | 21.05M |
| Ligand Pharmaceuticals, Inc. | 3.511M |